Dr. Berry on LHRH Antagonists Versus Agonists for Prostate Cancer

William R. Berry, MD, medical oncologist, Duke University, discusses determining when to use luteinizing hormone-releasing hormone (LHRH) antagonists versus agonists for patients with prostate cancer.

Before LHRH antagonists, there was a concern for patients who presented with metastatic disease, particularly metastatic disease in the bone, states Berry. Many of these patients would experience a surge of bone pain after starting therapy.

There is an indication to use the antagonist as they present with fewer symptoms than agonists, explains Berry.